Efficacy of Subcutaneous Secukinumab in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Results from the Randomized Placebo-controlled FUTURE 2 Study

To determine the effect of prior tumor necrosis factor inhibitor (TNFi) therapy on secukinumab efficacy in psoriatic arthritis (PsA). Patients were randomized to secukinumab 300 mg, 150 mg, 75 mg, or placebo. American College of Rheumatology 20 responses at Week 24 with secukinumab 300 mg, 150 mg, 7...

Full description

Saved in:
Bibliographic Details
Published in:Journal of rheumatology 2016-09, Vol.43 (9), p.1713-1717
Main Authors: Kavanaugh, Arthur, McInnes, Iain B, Mease, Philip J, Hall, Stephen, Chinoy, Hector, Kivitz, Alan J, Wang, Zailong, Mpofu, Shephard
Format: Article
Language:English
Subjects:
Adult
Aged
Antibodies, Monoclonal - administration & dosage
Antibodies, Monoclonal - therapeutic use
Antirheumatic Agents - therapeutic use
Arthritis, Psoriatic - drug therapy
Double-Blind Method
Female
Humans
Injections, Subcutaneous
Male
Middle Aged
Retreatment
Treatment Outcome
Tumor Necrosis Factor-alpha - antagonists & inhibitors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To determine the effect of prior tumor necrosis factor inhibitor (TNFi) therapy on secukinumab efficacy in psoriatic arthritis (PsA). Patients were randomized to secukinumab 300 mg, 150 mg, 75 mg, or placebo. American College of Rheumatology 20 responses at Week 24 with secukinumab 300 mg, 150 mg, 75 mg, and placebo were 58.2%, 63.5%, 36.9%, and 15.9% in TNFi-naive (n = 258), and 45.5%, 29.7%, 14.7%, and 14.3% in TNFi-exposed patients (n = 139), respectively. Week 52 responses with secukinumab 300 mg, 150 mg, and 75 mg were 68.7%, 79.4%, and 58.5% in TNFi-naive, and 54.5%, 37.8%, and 35.3% in TNFi-exposed patients, respectively. Secukinumab was efficacious in TNFi-naive and TNFi-exposed patients with PsA, with greatest improvements in TNFi-naive patients.
ISSN:0315-162X
1499-2752
DOI:10.3899/jrheum.160275